<DOC>
	<DOCNO>NCT01231594</DOCNO>
	<brief_summary>This rollover study design provide continued access GSK2118436 eligible subject BRAF mutation-positive tumor previously participate GlaxoSmithKline ( GSK ) -sponsored GSK2118436 study ( parent study ) , evidence progressive disease tolerate GSK2118436 parent study without significant toxicity . Subjects enrol appropriate cohort base upon treatment receive parent study . Safety assessment ( physical examination , vital sign , 12-lead electrocardiogram , echocardiogram , clinical laboratory assessment , monitor adverse event ) make throughout study . Clinical activity assess use local standard care image practice appropriate response criterion determine investigator .</brief_summary>
	<brief_title>A Rollover Study Provide Continued Treatment With GSK2118436 Subjects With BRAF Mutation-Positive Tumors</brief_title>
	<detailed_description />
	<mesh_term>Trametinib</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<mesh_term>Antineoplastic Agents</mesh_term>
	<criteria>Has provide sign write informed consent study Has demonstrate compliance study drug ( ) , treatment visit schedule , requirement restriction list consent form Is currently participate GSKsponsored study GSK2118436 Currently evidence progressive disease , determine investigator , follow previous treatment GSK2118436 ( either monotherapy part combination treatment regimen ) For Cohort C : Subjects must calcium phosphate product ( CPP ) &lt; 4.4 mmol^2/L^2 ( 55 mg^2/dL^2 ) continue treatment GSK1120212 Continued ability swallow retain orally administer study drug ( ) clinically significant GI abnormality may alter absorption malabsorption syndrome major resection stomach bowel Women childbearing potential men reproductive potential must willing continue practice acceptable method birth control study NOTE : Oral contraceptive reliable due potential drugdrug interaction GSK2118436 Women childbearing potential must negative serum pregnancy test time transition study first dose study treatment French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category Permanent discontinuation GSK2118436 parent study due toxicity disease progression Local access commercially available GSK2118436 Currently receive treatment prohibit medication ( ) Any unresolved toxicity &gt; Grade 2 ( National Cancer InstituteCommon Toxicity Criteria Adverse Events [ NCICTCAE ] , version 4.0 ) parent study treatment , except alopecia , need approve GSK Medical Monitor Uncontrolled diabetes , hypertension medical condition time transition study may interfere assessment toxicity Presence rheumatoid arthritis Corrected QT ( QTc ) interval &gt; /= 480 msec time transition study Left ventricular ejection fraction ( LVEF ) &lt; /= institutional low limit normal ( LLN ) ECHO time transition study Class II , III , IV heart failure define New York Heart Association ( NYHA ) functional classification system time transition study Pregnant lactate female Any serious and/or unstable preexist medical , psychiatric disorder condition time transition study could interfere subject 's safety , obtain informed consent compliance study procedure , opinion investigator GSK Medical Monitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>BRAF Inhibitor</keyword>
	<keyword>Cancer</keyword>
	<keyword>Safety</keyword>
	<keyword>GSK2118436</keyword>
	<keyword>BRAF mutation positive tumor</keyword>
</DOC>